Medical Weight Loss Has Changed. Here’s What Supervised Treatment Actually Looks Like.

The conversation about weight loss medications has shifted dramatically in the past three years. Semaglutide — the active ingredient in Ozempic and Wegovy — and tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, have produced results in clinical trials that were previously considered implausible for a pharmaceutical intervention. A 2021 New England Journal of Medicine trial found that patients using semaglutide lost an average of nearly 15% of their body weight over 68 weeks. Tirzepatide trials have demonstrated average weight loss approaching 22%, with some participants losing over 25% of their starting weight.

These are not modest improvements. They are clinically significant reductions in a measure — excess body weight — that carries documented associations with cardiovascular disease, type 2 diabetes, hypertension, sleep apnea, certain cancers, and joint disease. The emergence of effective pharmacological options for weight management represents a genuine shift in what medicine can offer patients who have struggled with weight despite sustained effort.

At My Concierge MD in Beverly Hills, Dr. David Nazarian, MD — a board-certified internal medicine and concierge physician with over a decade of experience — oversees medically supervised weight loss programs that include both branded and compounded semaglutide and tirzepatide, integrated with comprehensive monitoring and the kind of individualized clinical oversight that determines whether a patient achieves the results the medications are capable of delivering.

What These Medications Do — and Why Supervision Matters

GLP-1 receptor agonists like semaglutide work by mimicking the glucagon-like peptide-1 hormone, which plays several roles in appetite and metabolism regulation. They slow gastric emptying, increase satiety signals to the brain, and reduce the neurological reward response associated with high-calorie food. The result for most patients is a meaningful reduction in appetite — not the white-knuckled caloric restriction of traditional dieting, but a genuine shift in hunger signals that makes eating less feel physiologically manageable rather than a constant act of willpower.

Tirzepatide acts on two receptors simultaneously — GLP-1 and GIP — which produces additional effects on insulin sensitivity and fat storage that appear to contribute to its superior efficacy profile relative to semaglutide in direct comparison trials.

Why does medical supervision matter for medications this effective? Several reasons that are clinically meaningful:

• Appropriate candidacy assessment. Not every patient is an appropriate candidate for GLP-1 medications. Personal or family history of medullary thyroid carcinoma or MEN2, certain pancreatic conditions, and specific medication interactions require evaluation before prescribing. A physician who knows the patient’s full history makes this determination with appropriate rigor; an online questionnaire does not.
• Dosing management. Both medications are titrated — started at low doses and increased gradually to minimize gastrointestinal side effects, which are common but manageable with proper titration. The pace of dose escalation should be calibrated to the individual patient’s response, not a one-size-fits-all schedule from a remote prescriber who never speaks with the patient.
• Monitoring during treatment. Meaningful weight loss produces changes in blood pressure, blood sugar, liver enzymes, and kidney function that warrant periodic monitoring. Patients whose metabolic parameters are shifting — particularly those with pre-existing conditions like diabetes or hypertension — may need medication adjustments as their weight changes.
• Nutritional and metabolic context. Weight loss medications work optimally in the context of dietary awareness and lifestyle modifications that Dr. Nazarian’s team addresses as part of the program. Patients who lose significant weight rapidly without attention to protein intake and resistance exercise risk losing lean muscle mass alongside fat — an outcome that affects metabolic rate and long-term results.

Compounded Options and Access

Branded GLP-1 medications have experienced significant demand-driven supply constraints, and their retail cost without insurance coverage is prohibitive for many patients. My Concierge MD offers access to high-purity compounded semaglutide and tirzepatide from FDA-registered U.S. peptide pharmacies — medications that contain the same active compounds at a fraction of the branded cost, available with a valid medical prescription following a proper clinical evaluation.

The availability of compounded options has opened medically supervised GLP-1 treatment to patients who would otherwise face access barriers — while maintaining the clinical oversight that distinguishes medically supervised treatment from online pill mills or unmonitored supplementation.

What Results Realistically Look Like

Clinical trial data describes average outcomes in large populations. Individual results vary based on starting weight, metabolic factors, medication adherence, lifestyle context, and biological response. Most patients on appropriate doses of semaglutide or tirzepatide, with concurrent dietary attention and physician monitoring, achieve meaningful weight loss within the first 12 weeks — with results continuing to accumulate through the full treatment course.

Dr. Nazarian evaluates each weight loss patient individually, establishing realistic goals based on their specific clinical profile, discussing what the treatment process involves, and following up at regular intervals to assess response and make adjustments. Patients have direct access to him for questions between appointments — a feature of concierge medicine that is particularly relevant during a treatment process where individual responses vary and questions arise.

Schedule Your Weight Loss Consultation

Call us at (310) 299-8959 or reach out through our patient portal to schedule a weight loss consultation with Dr. Nazarian. We serve patients throughout Los Angeles and Beverly Hills, with house call and hotel visit options available. The evaluation is the first step — a thorough assessment of whether GLP-1 therapy is appropriate for your specific situation, what the program involves, and what a realistic outcome looks like for you.

Medically reviewed by David Nazarian, MD on September 28, 2026